Nuformix Plc Competitors

SB Drug Discovery (part of Sygnature Discovery) is an industry leader in specialist contract research, providing critical data for novel drug development through cell line generation, assay development and compound screening services. With a global reputation for outstanding customer service, our clients know their research is in the best hands.Using the latest technologies, our expert teams deliver fast, reliable and robust data customized to meet our clients' requirements and are on-hand to discuss options at every stage.Together, we are driving the discovery of tomorrow's novel therapeutics - today.

Pathios Therapeutics are world-leading experts with unique expertise in GPCR drug development, focused on GPR65 as a high-value immunology target with robust genetic links to multiple human diseases. Our clinical-stage oncology programme leverages cutting-edge proprietary genetic insights, transcriptomics, and functional immunology of GPR65 as a key immune cell sensor of acidosis in multiple pathological environments, to bring about a revolutionary new approach to treating a broad spectrum of cancers. We are also building an emerging pipeline in neuroinflammatory and neurodegenerative disorders leveraging the broader immunological roles of this receptor in cell types such as microglia.Based in in Oxford, UK, Pathios combines a team of experienced scientific leaders with strategic external partnerships. We are supported by top tier investors Canaan, Brandon Capital Partners and Bristol Myers Squibb. Pathios is part of the M:M Bio ecosystem, which integrates experienced drug discovery expertise with stage-appropriate, agile, operational infrastructure that results in companies that are efficient, cost effective, focused and great places to work.

InoCardia is an organisation dedicated to bringing superior, predictive cardiac contractility to early drug discovery. By manipulating pre- and after-load, and by directly measuring microscopic changes in the force of contraction, we provide a unique suite of cardiac contractility data from the same myocyte - including the Work Loop model. We have received multiple grant awards and have recently completed a 3-year, NC3R/InnovateUK project to miniaturise the Work Loop platform. This project enabled the ground-breaking ca rdiac contractome AI concept supported by EIT Digital .